In a mutational study that included different types of gynecological cancers, ovarian, breast, and uterine tumors, seven polymorphisms were identified within the coding sequence of BARD1, including somatic missense mutations and germline alterations. This evidence concerns the gene BARD1 and female reproductive organ cancer.